News Image

Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.

By Mill Chart

Last update: Apr 26, 2024

In this article we will dive into INSULET CORP (NASDAQ:PODD) as a possible candidate for growth investing. Investors should always do their own research, but we noticed INSULET CORP showing up in our strong growth, ready to breakout screen, which makes it worth to investigate a bit more.

Growth Assessment of NASDAQ:PODD

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:PODD has earned a 9 for growth:

  • The Earnings Per Share has grown by an impressive 455.10% over the past year.
  • Measured over the past years, PODD shows a very strong growth in Earnings Per Share. The EPS has been growing by 122.39% on average per year.
  • The Revenue has grown by 30.02% in the past year. This is a very strong growth!
  • The Revenue has been growing by 24.66% on average over the past years. This is a very strong growth!
  • The Earnings Per Share is expected to grow by 24.56% on average over the next years. This is a very strong growth
  • PODD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.91% yearly.

Exploring NASDAQ:PODD's Health

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:PODD has earned a 5 out of 10:

  • PODD has an Altman-Z score of 4.97. This indicates that PODD is financially healthy and has little risk of bankruptcy at the moment.
  • PODD has a Altman-Z score of 4.97. This is in the better half of the industry: PODD outperforms 78.97% of its industry peers.
  • PODD's Debt to FCF ratio of 38.79 is fine compared to the rest of the industry. PODD outperforms 69.23% of its industry peers.
  • A Current Ratio of 3.51 indicates that PODD has no problem at all paying its short term obligations.
  • A Quick Ratio of 2.62 indicates that PODD has no problem at all paying its short term obligations.

Analyzing Profitability Metrics

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:PODD has achieved a 8:

  • PODD's Return On Assets of 7.97% is amongst the best of the industry. PODD outperforms 89.23% of its industry peers.
  • With an excellent Return On Equity value of 28.16%, PODD belongs to the best of the industry, outperforming 97.95% of the companies in the same industry.
  • PODD's Return On Invested Capital of 7.36% is amongst the best of the industry. PODD outperforms 85.64% of its industry peers.
  • The last Return On Invested Capital (7.36%) for PODD is above the 3 year average (4.58%), which is a sign of increasing profitability.
  • The Profit Margin of PODD (12.16%) is better than 89.23% of its industry peers.
  • PODD's Profit Margin has improved in the last couple of years.
  • PODD has a better Operating Margin (12.96%) than 83.59% of its industry peers.
  • In the last couple of years the Operating Margin of PODD has grown nicely.
  • PODD has a better Gross Margin (68.35%) than 76.92% of its industry peers.

Why is NASDAQ:PODD a setup?

In addition to the Technical Rating, ChartMill provides a Setup Rating for each stock. This rating, ranging from 0 to 10, assesses the extent of consolidation in the stock based on multiple short-term technical indicators. Currently, NASDAQ:PODD has a 7 as its setup rating:

Although the technical rating is bad, PODD does present a nice setup opportunity. Prices have been consolidating lately and the volatility has been reduced. There is a support zone below the current price at 164.16, a Stop Loss order could be placed below this zone.

More Strong Growth stocks can be found in our Strong Growth screener.

Our latest full fundamental report of PODD contains the most current fundamental analsysis.

Our latest full technical report of PODD contains the most current technical analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

INSULET CORP

NASDAQ:PODD (5/3/2024, 7:12:59 PM)

After market: 174.43 0 (0%)

174.43

+1.01 (+0.58%)

PODD News

News Image8 days ago - ChartmillWhy NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.

Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?

News Image17 days ago - InvestorPlace3 Weight-Loss ETFs to Profit From the Obesity Drug Boom

Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.

News Image19 days ago - InvestorPlace7 Stable Stocks for 50% Returns by Early 2025

These 7 stable stocks also offer 50% returns according to analysts according to analysts tasked with following their respective industries.

News Imagea month ago - Insulet CorporationInsulet to Announce First Quarter 2024 Financial Results on May 9, 2024
News Image2 months ago - Market News VideoWednesday Sector Laggards: Healthcare, Utilities
News Image2 months ago - Insulet CorporationInsulet Appoints Ana Maria Chadwick as Chief Financial Officer
News Image2 months ago - Market News VideoTuesday Sector Laggards: Technology & Communications, Healthcare
News Image2 months ago - Market News VideoWednesday Sector Laggards: Technology & Communications, Healthcare
News Image2 months ago - Market News VideoPODD July 2025 Options Begin Trading
News Image2 months ago - Insulet CorporationInsulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
News Image2 months ago - Insulet CorporationInsulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
News Image2 months ago - The Motley FoolIs It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?

A handful of large-cap stocks are now on sale. The discount, however, doesn't necessarily make them worth buying.

PODD Links
Follow us for more